Today's Top Stories


Hot Topics


Comment & Analysis »

GlobalData Healthcare

New class of diabetes drugs show heart failure prevention signal

After the unexpected cardiovascular (CV) benefit observed in the EMPA-REG OUTCOME study of the SGLT-2 inhibitor, empagliflozin, there has been a surge of research trying to decipher whether...

New class of diabetes drugs show heart failure prevention signal
GBI Research

Are anti-ageing drugs real, and can they prevent cancer?

Are anti-ageing drugs real, and can they prevent cancer?
GlobalData Healthcare

Aurinia poised to independently commercialise voclosporin in lupus nephritis

Aurinia poised to independently commercialise voclosporin in lupus nephritis
GlobalData Healthcare

PTC Therapeutics' Translarna fails phase III trial for cystic fibrosis

PTC Therapeutics' Translarna fails phase III trial for cystic fibrosis
Naga Divya Tirumalaraju

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial

Company Releases »

Benefits of Trehalose

Pfanstiehl
Benefits of Trehalose

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

SYSTAG Systems Technik
ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

Analysing Polysaccharides Using OMNISEC

Malvern Instruments Analysing Polysaccharides Using OMNISEC

Optimising Development Resources for Efficient Product Development

SYSTAG Systems Technik
Optimising Development Resources for Efficient Product Development

Contract Manufacturing Of Biopharmaceuticals

Biovian Contract Manufacturing Of Biopharmaceuticals

Drugdevelopment Insights »

Drugdevelopment Industry Reports »

Report: Rheumatoid arthritis market projected to reach $28.5bn by 2025

Report: Rheumatoid arthritis market projected to reach $28.5bn by 2025

C. difficile pipeline vaccines could offer an alternative to antibiotics

C. difficile pipeline vaccines could offer an alternative to antibiotics

Novavax driving to achieve significant market presence in respiratory complications market

Novavax driving to achieve significant market presence in respiratory complications market

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?








cachename:HomePagecachekey:rd-1665407042_1729060782_rd-488908060_1460672566_ap1460672566_1729060782_1903286115